共 50 条
- [41] EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDYGASTROENTEROLOGY, 2021, 160 (06) : S350 - S350Peyrin-Biroulet, LaurentLoftus, Edward V.Danese, SilvioVermeire, SeverineSandborn, William J.Fogel, Ronald P.Nijhawan, SandeepKempinski, RadoslawFilip, RafalHospodarskyy, IhorMcNally, JohnYun, ChoheeZhao, SallyLiu, XiaopengTasset, Chantal T.Besuyen, RobinWatanabe, MamoruSchreiber, StefanRogler, GerhradHibi, ToshifumiFeagan, Brian G.
- [42] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60Sandborn, W. J.Sands, B.Kobayashi, T.Tuttle, J.Schmitz, J.Durante, M.Higgs, R.Canavan, J. B.Siegel, R.Ferrante, M.
- [43] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISGASTROENTEROLOGY, 2018, 154 (06) : S380 - S381Watanabe, MamoruMotoya, SatoshiWatanabe, KenjiOgata, HaruhikoKanai, TakanoriMatsui, ToshiyukiSuzuki, YasuoShikamura, MitsuhiroIgeta, MasatakaOda, KazunoriHori, TetsuharuAraki, TakahiroHibi, Toshifumi
- [44] BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALSGASTROENTEROLOGY, 2023, 164 (06) : S213 - S213Rubin, David T.Hindryckx, PieterHibi, ToshifumiMcGinnis, KimGibble, Theresa H.Keohane, AnthonyRegueiro, Miguel D.
- [45] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMANDGASTROENTEROLOGY, 2024, 166 (05) : S238 - S238Schreiber, StefanPanaccione, RemoParkes, Gareth C.Peyrin-Biroulet, LaurentFerrante, MarcHisamatsu, TadakazuSiegmund, BrittaKalabic, JasminaLevine, PhillipNeimark, EzequielWallace, KoriChen, SuCheng, LingDuan, W. RachelArmuzzi, AlessandroBiedermann, LucLoftus, Edward V.Melmed, GilLouis, Edouard
- [46] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction studyJOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422Sridhar, S.Hart, A.Venkat, S.Huang, K. H. G.Yarandi, S.Germinaro, M.Vetter, M.Rubin, D. T.Dignass, A.Cua, D.Freeman, T.Waterworth, D.Mcrae, B.Verstockt, B.Branigan, P.
- [47] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S521 - S522Vermeire, SeverineDanese, SilvioZhou, WenYao, XuanIlo, DapoLiu, JohnHebuterne, XavierLindsay, JamesSanchez-Gonzalez, YuriHiggins, Peter D.Colombel, Jean-FredericPanaccione, Remo
- [48] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trialsJOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646Friedrich, S.Chua, L.Zhang, X. C.
- [49] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALSGASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218Friedrich, StuartChua, LaiyiZhang, Xin
- [50] The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12JOURNAL OF CROHNS & COLITIS, 2022, 16 : I025 - I026Dignass, A.Rubin, D.Bressler, B.Huang, K. H.Shipitofsky, N.Germinaro, M.Zhang, H.Johanns, J.Feagan, B.Sandborn, W.Sands, B.Hisamatsu, T.Lichtenstein, G.Panes, J.Allegretti, J.